NCT03370276 2026-03-10
Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
Clinical Trials
11 trialsNCT04391049 2026-01-30
Testing the Addition of the Anti-cancer Viral Therapy Telomelysinâ„¢ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery
NRG Oncology
Phase 1 Active not recruiting
NCT03509467 2025-12-19
Using MC1R Genotype to Impact Melanoma Risk Behavior
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Completed
NCT02837042 2022-06-21
Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma
University of Alabama at Birmingham
Phase 2 Terminated
NCT01111058 2020-04-07
Everolimus Versus Placebo in Head and Neck Cancer
University of Chicago
Phase 2 Terminated
NCT01581970 2019-09-11
Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT01016769 2019-06-26
Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00661427 2018-01-11
Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00591149 2017-06-14
Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer
University of Kansas Medical Center
Phase 2 Terminated
NCT00815295 2014-12-08
Study of Sorafenib/Cetuximab in Head and Neck Cancer
Duke University
Phase 1/2 Completed
NCT00485485 2012-08-07
Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Completed